Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP (July 2013). "Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance". Gastroenterology. 145 (1): 121–128.e1. doi:10.1053/j.gastro.2013.03.050. PMID23562754.
Wang H, Kong QZ, Li YY, Yang XY, Zuo XL (March 2024). "High-dose dual therapy versus bismuth-containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta-analysis". J Dig Dis. 25 (3): 163–175. doi:10.1111/1751-2980.13263. PMID38577962.
Zhou BG, Jiang X, Ding YB, She Q, Li YY (2024). "Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis". Helicobacter. 29 (1): e13040. doi:10.1111/hel.13040. PMID37983865. S2CID265308205.
B Y, H A (2010). "Efficacy of probiotics in Helicobacter pylori eradication therapy". Turk J Gastroenterol. 21 (3): 212–217. doi:10.4318/tjg.2010.0090. PMID20931422.
Borody TJ, P. Cole, S. Noonan, A. Morgan, J. Lenne, L. Hyland, S. Brandl, E. G. Borody, L. L. George (October 16, 1989). "Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication". Medical Journal of Australia. 151 (8): 431–435. doi:10.5694/j.1326-5377.1989.tb101251.x. PMID2687668. S2CID26066525.
Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP (July 2013). "Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance". Gastroenterology. 145 (1): 121–128.e1. doi:10.1053/j.gastro.2013.03.050. PMID23562754.
Wang H, Kong QZ, Li YY, Yang XY, Zuo XL (March 2024). "High-dose dual therapy versus bismuth-containing quadruple therapy for the eradication of Helicobacter pylori: A systematic review and meta-analysis". J Dig Dis. 25 (3): 163–175. doi:10.1111/1751-2980.13263. PMID38577962.
Zhou BG, Jiang X, Ding YB, She Q, Li YY (2024). "Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis". Helicobacter. 29 (1): e13040. doi:10.1111/hel.13040. PMID37983865. S2CID265308205.
B Y, H A (2010). "Efficacy of probiotics in Helicobacter pylori eradication therapy". Turk J Gastroenterol. 21 (3): 212–217. doi:10.4318/tjg.2010.0090. PMID20931422.
Borody TJ, P. Cole, S. Noonan, A. Morgan, J. Lenne, L. Hyland, S. Brandl, E. G. Borody, L. L. George (October 16, 1989). "Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication". Medical Journal of Australia. 151 (8): 431–435. doi:10.5694/j.1326-5377.1989.tb101251.x. PMID2687668. S2CID26066525.
Zhou BG, Jiang X, Ding YB, She Q, Li YY (2024). "Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis". Helicobacter. 29 (1): e13040. doi:10.1111/hel.13040. PMID37983865. S2CID265308205.
Borody TJ, P. Cole, S. Noonan, A. Morgan, J. Lenne, L. Hyland, S. Brandl, E. G. Borody, L. L. George (October 16, 1989). "Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication". Medical Journal of Australia. 151 (8): 431–435. doi:10.5694/j.1326-5377.1989.tb101251.x. PMID2687668. S2CID26066525.